NeoRx, Janssen Pharmaceutica N.V. deal

The companies will develop NERX's Avicidin cancer compound (yttrium-90 beta-emitting radionuclide) on a worldwide basis.

NERX received $10 million

Read the full 194 word article

How to gain access

Continue reading with a
two-week free trial.